Logo image of APS.CA

APTOSE BIOSCIENCES INC (APS.CA) Stock Price, Quote, News and Overview

TSX:APS - Toronto Stock Exchange - CA03835T3091 - Common Stock - Currency: CAD

0.255  -0.03 (-8.93%)

APS.CA Quote, Performance and Key Statistics

APTOSE BIOSCIENCES INC

TSX:APS (2/14/2025, 7:00:00 PM)

0.255

-0.03 (-8.93%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High2.65
52 Week Low0.19
Market Cap15.35M
Shares60.18M
Float56.51M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)03-24 2025-03-24/amc
IPO06-04 1993-06-04


APS.CA short term performance overview.The bars show the price performance of APS.CA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30 -40 -50

APS.CA long term performance overview.The bars show the price performance of APS.CA in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of APS.CA is 0.255 CAD. In the past month the price decreased by -15%. In the past year, price decreased by -90.27%.

APTOSE BIOSCIENCES INC / APS Daily stock chart

APS.CA Latest News, Press Relases and Analysis

News Image
5 days ago - Aptose Biosciences, Inc.

Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility

Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility ...

News Image
6 days ago - Aptose Biosciences, Inc.

Aptose’s Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial

Aptose’s Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial ...

News Image
a month ago - Aptose Biosciences, Inc.

Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial

TUS+VEN+AZA triplet has potential as frontline therapy to treat large, mutationally diverse populations of AML

News Image
a month ago - Aptose Biosciences, Inc.

Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial

Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial ...

APS.CA Competitors/Peers

The largest stocks on the Canadian markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
FRX.CA FENNEC PHARMACEUTICALS INC N/A 269.79M
EDT.CA SPECTRAL MEDICAL INC N/A 182.24M
EPRX.CA EUPRAXIA PHARMACEUTICALS INC N/A 161.49M
TH.CA THERATECHNOLOGIES INC N/A 114.49M
MDNA.CA MEDICENNA THERAPEUTICS CORP N/A 104.81M
ONC.CA ONCOLYTICS BIOTECH INC N/A 88.82M
COV.CA COVALON TECHNOLOGIES LTD 27.55 83.02M
MBX.CA MICROBIX BIOSYSTEMS INC 18.33 73.96M
MSCL.CA SATELLOS BIOSCIENCE INC N/A 73.25M
MDCX.CA MEDICUS PHARMA LTD N/A 54.25M
SVA.CA SERNOVA BIOTHERAPEUTICS INC N/A 52.45M
HBP.CA HELIX BIOPHARMA CORP N/A 50.37M

About APS.CA

Company Profile

APS logo image Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. The company is headquartered in North York, Ontario and currently employs 35 full-time employees. The firm's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. Its lead clinical-stage compound Tuspetinib (TUS), is an oral kinase inhibitor that has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. Its Luxeptinib (LUX) is being developed for the treatment of patients with certain B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and certain non-Hodgkin’s lymphomas (NHL) who are resistant or intolerant to conventional treatments.

Company Info

APTOSE BIOSCIENCES INC

251 Consumers Rd Suite 1105

North York ONTARIO M2J 4R3 CA

CEO: William G. Rice

Employees: 35

Company Website: https://aptose.com/

Investor Relations: https://www.aptose.com/investors

Phone: 16474799828

APS.CA FAQ

What is the stock price of APS.CA?

The current stock price of APS.CA is 0.255 CAD.


What is the symbol for APTOSE BIOSCIENCES INC stock?

The exchange symbol of APTOSE BIOSCIENCES INC is APS and it is listed on the Toronto Stock Exchange exchange.


On which exchange is APS.CA stock listed?

APS.CA stock is listed on the Toronto Stock Exchange exchange.


Is APS.CA a good stock to buy?

Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for APS.CA, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of APS.CA.


Does APS.CA stock pay dividends?

APS.CA does not pay a dividend.


When does APS.CA stock report earnings?

APS.CA will report earnings on 2025-03-24, after the market close.


What is the Price/Earnings (PE) ratio of APS.CA?

APS.CA does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.21).


APS.CA Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

APS.CA Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to APS.CA. APS.CA has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

APS.CA Financial Highlights

Over the last trailing twelve months APS.CA reported a non-GAAP Earnings per Share(EPS) of -4.21. The EPS decreased by 62.55% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -327.57%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%78.98%
Sales Q2Q%N/A
EPS 1Y (TTM)62.55%
Revenue 1Y (TTM)N/A

APS.CA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 83% to APS.CA. The Buy consensus is the average rating of analysts ratings from 7 analysts.


Ownership
Inst Owners15.08%
Ins Owners0.57%
Short Float %N/A
Short RatioN/A
Analysts
Analysts82.86
Price Target5.92 (2221.57%)
EPS Next Y76.35%
Revenue Next YearN/A